Abstract:Objectives and design:Developing an effective HIV-1 vaccine that elicits broadly neutralizing HIV-1 human antibodies (bnAbs) remains a challenging goal. Extensive studies on HIV-1 have revealed various strategies employed by the virus to escape host immune surveillance. Here, we investigated the human antibody gene repertoires of uninfected and HIV-1-infected individuals at genomic DNA (gDNA) and cDNA levels by deep sequencing followed by high-throughput sequence analysis to determine the frequencies of putative germline antibody genes of known HIV-1 monoclonal bnAbs (bnmAbs).Methods:Combinatorial gDNA and cDNA antibody libraries were constructed using the gDNAs and mRNAs isolated from uninfected and HIV-1-infected human peripheral blood mononuclear cells (PBMCs). All libraries were deep sequenced and sequences analysed using IMGT/HighV-QUEST software (http://imgt.org/HighV-QUEST/index.action). The frequencies of putative germline antibodies of known bnmAbs in the gDNA and cDNA libraries were determined.Results and conclusion:The human gDNA antibody libraries were more diverse in heavy and light chain V-gene lineage usage than the cDNA libraries, indicating that the human gDNA antibody gene repertoires may have more potential than the cDNA repertoires to develop HIV-1 bnAbs. The frequencies of the heavy and kappa and lambda light chain variable regions with identical V(D)J recombinations to known HIV-1 bnmAbs were extremely low in human antibody gene repertoires. However, we found relatively high frequencies of the heavy and kappa and lambda light chain variable regions that used the same V-genes and had the same CDR3 lengths as known HIV-1 bnmAbs regardless of (D)J-gene usage. B-cells bearing B-cell receptors of such heavy and kappa and lambda light chain variable regions may be stimulated to induce HIV-1 bnAbs. (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins

HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen

Targeted selection of HIV-specific antibody mutations by engineering B cell maturation

Vaccination induces broadly neutralizing antibody precursors to HIV gp41

A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses

Ontogeny‐based immunogens for the induction of V2‐directed HIV broadly neutralizing antibodies

A vaccine strategy for inducing broadly neutralizing antibodies against HIV

Vaccine priming of rare HIV broadly neutralizing antibody precursors in nonhuman primates

Vaccination induces HIV broadly neutralizing antibody precursors in humans

The Potential Of The Human Immune System To Develop Broadly Neutralizing Hiv-1 Antibodies: Implications For Vaccine Development

Germline-targeting HIV vaccination induces neutralizing antibodies to the CD4 binding site

Membrane-bound mRNA immunogens lower the threshold to activate HIV Env V2 apex-directed broadly neutralizing B cell precursors in humanized mice

Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo

mRNA-LNP HIV-1 trimer boosters elicit precursors to broad neutralizing antibodies

Mutation-guided vaccine design: A process for developing boosting immunogens for HIV broadly neutralizing antibody induction

Vaccine induction of CD4-mimicking HIV-1 broadly neutralizing antibody precursors in macaques

HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies

Augmenting Neutralization Breadth Against Diverse HIV-1 by Increasing the Ab-Ag Interface on V2

Identification of Non-Hiv Immunogens That Bind to Germline B12 Predecessors and Prime for Elicitation of Cross-Clade Neutralizing Hiv-1 Antibodies

Tracing HIV-1 strains that imprint broadly neutralizing antibody responses

Vaccination induces maturation in a mouse model of diverse unmutated VRC01-class precursors to HIV-neutralizing antibodies with >50% breadth

Preservation of memory B cell homeostasis in an individual producing broadly neutralising antibodies against HIV-1